Skip to main content

Month: March 2026

vTv Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

Received $20.0 million in February 2026 from Newsoara under an amended licensing agreement Expect to complete enrollment in the CATT1 Phase 3 trial in the third quarter of 2026  Strengthened balance sheet provides funding runway well past the anticipated CATT1 Phase 3 topline readout HIGH POINT, N.C., March 10, 2026 (GLOBE NEWSWIRE) — vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliatin, a novel, potential first-in-class oral adjunctive therapy to insulin being investigated for the treatment of type 1 diabetes (“T1D”), today reported financial results for the fourth quarter and full year ended December 31, 2025, and provided an update on recent corporate developments. “In 2025, vTv delivered meaningful clinical and corporate progress that positions...

Continue reading

Skye Bioscience Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Initiated higher-dose CBeyond Expansion Study (Part C) to generate higher-exposure human safety and pharmacokinetic data with 400 mg and 600 mg IV cohorts; Received written FDA Type C meeting minutes; feedback is informing key Phase 2b combination design elements and the Company’s ongoing evaluation of a potential add-on development path with incretin therapy; Presented new body composition data demonstrating differentiated weight maintenance profile for patients that have discontinued combination therapy; Proof-of-concept preclinical data validates Skye’s antigen-peptide conjugate platform, a single unimolecular therapeutic of nimacimab-GLP1RA that delivers additive weight-loss.SAN DIEGO, March 10, 2026 (GLOBE NEWSWIRE) — Skye Bioscience, Inc. (NASDAQ: SKYE) (“Skye” or the “Company”), a clinical stage biopharmaceutical...

Continue reading

SIGA Reports Financial Results for Three and Twelve Months Ended December 31, 2025 and Provides Business Update

Generated TPOXX Product Revenues of $88 Million in 2025  Received $13 Million International Procurement Order for Oral TPOXX in January 2026   Corporate Update Conference Call Today at 4:30 PM ETNEW YORK, March 10, 2026 (GLOBE NEWSWIRE) — SIGA Technologies, Inc. (SIGA) (Nasdaq: SIGA), a commercial-stage pharmaceutical company, today reported financial results for the three and twelve months ended December 31, 2025. “In 2025, we continued to advance SIGA’s key long-term priorities, including securing $27 million in additional U.S. Government funding to support development activities, while generating $88 million in product revenues and $24 million in pre-tax operating income,” stated Diem Nguyen, Chief Executive Officer. “In 2026, we are focused on building on our long-standing track record as a successful partner to the...

Continue reading

Toll Brothers Grand Opens Two Collections of Single-Family Homes at The Crossing at Coal Mountain in Cumming, Georgia

CUMMING, Ga., March 10, 2026 (GLOBE NEWSWIRE) — Toll Brothers, Inc. (NYSE:TOL), the nation’s leading builder of luxury homes, today announced the grand opening of Toll Brothers at the Crossing at Coal Mountain, in Forsyth County, Georgia. The first two collections of single-family homes, the Heartland and Magnolia Collections, along with the Tearose, Sweetwater, and Willowbrook model homes are now open at 3505 Settingdown Road in Cumming. Two additional townhome collections in the community are anticipated to open for sale in late Spring.Toll Brothers at The Crossing at Coal Mountain will feature four distinctive collections of elegant single-family homes and future townhomes to complement a variety of lifestyles. The Heartland Collection features elegant single-family homes with 3 to 4 spacious bedrooms, 2.5 to 3.5 bathrooms,...

Continue reading

Dassault Aviation Unveils the Falcon 10X – New Top of the Line Falcon

Dassault Aviation Unveils the Falcon 10X New Top of the Line Falcon A New Standard of Comfort, Performance and Innovation in Business Aviation (Saint-Cloud, France, March 10, 2026) – In a dramatic unveiling before more than 400 customers, partners and aviation leaders gathered in a new production hall in Bordeaux-Mérignac, Dassault Aviation has rolled out the Falcon 10X—its most ambitious business jet ever. As the drape lifted at 8:00 p.m. CET, the aircraft emerged as a bold new benchmark for the future of long-range business aviation. The Falcon 10X introduces the largest, most comfortable, and most versatile cabin ever designed in a purpose-built business jet—redefining what passengers can expect from time spent in the air. “The objective,” says Dassault President & CEO Eric Trappier, “is to allow passengers to experience time on...

Continue reading

Technip Energies publishes its 2025 Annual Report

Technip Energies (PARIS:TE) (the “Company”), a global technology & engineering powerhouse leading in energy and decarbonization infrastructure, today published its 2025 Annual Report. The Company filed its 2025 Annual Report with the Autoriteit Financiële Markten (AFM) in the Netherlands and the Autorité des marchés financiers (AMF) in France. The 2025 Annual Report is available at https://investors.technipenergies.com/shareholder-information/reports-and-presentations. Technip Energies will hold its Annual General Meeting in Schiphol, the Netherlands on May 5, 2026. The convening notice, agenda and all related documents will be available at https://investors.technipenergies.com/shareholder-information/agm on March 24, 2026. About Technip Energies Technip Energies is a global technology and engineering powerhouse. With leadership positions...

Continue reading

BioXcel Therapeutics Announces Approximately $8.0 Million Registered Direct Offering

NEW HAVEN, Conn., March 10, 2026 (GLOBE NEWSWIRE) — BioXcel Therapeutics, Inc. (the “Company”) (Nasdaq: BTAI), a biopharmaceutical company built on artificial intelligence to develop transformative medicines in neuroscience, today announced that it has entered into a securities purchase agreement with an institutional investor for the purchase and sale in a registered direct offering of 4,500,785 shares (the “Shares”) of common stock, par value $0.001 per share (“Common Stock”) (or common stock equivalents in lieu thereof), and accompanying warrants (the “Accompanying Warrants”) to purchase up to 4,500,785 shares of Common Stock at a combined offering price of $1.739 per Share (or per common stock equivalent in lieu thereof) and Accompanying Warrant. The Accompanying Warrants will have an exercise price of $1.614 per share of Common...

Continue reading

Mining Inspectorate Recommends Mining Lease Approval for Leading Edge Materials’ Norra Karr Heavy Rare Earth Elements Project- Submits to the Swedish Government for a Final Decision

MINING INSPECTORATE RECOMMENDS MINING LEASE APPROVAL FOR LEADING EDGE MATERIALS’ NORRA KÄRR HEAVY RARE EARTH ELEMENTS PROJECT – SUBMITS TO THE SWEDISH GOVERNMENT FOR A FINAL DECISION Vancouver, March 10, 2026 – Leading Edge Materials Corp. (“Leading Edge Materials” or the “Company”) (TSXV: LEM) (Nasdaq First North: LEMSE) (OTCQB: LEMIF) (FRA: 7FL) is pleased to announce that The Swedish Mining Inspectorate (Sw. Bergsstaten) has chosen to submit the Company’s 100% owned Swedish subsidiary Greenna Mineral AB’s (“GMAB”) application for an Exploitation Concession for Norra Kärr to the Swedish Government for a final decision. The Mining Inspectorate itself recommends in its decision that the application (Norra Kärr K nr 2) should be approved. This follows the positive consultation responses from the County Administrative Boards (“CABs”)...

Continue reading

Medline Inc. announces closing of secondary offering of Class A common stock and full exercise of underwriters’ option to purchase additional shares

NORTHFIELD, Ill., March 10, 2026 (GLOBE NEWSWIRE) — Medline Inc. (Nasdaq: MDLN) (“Medline”) announced today that it has closed its secondary offering of 86,250,000 shares of Medline Inc.’s Class A common stock by certain selling stockholders affiliated with Blackstone Inc., The Carlyle Group Inc., Hellman & Friedman LLC and a wholly owned subsidiary of the Abu Dhabi Investment Authority (the “Selling Stockholders”) at a price to the public of $41.00 per share, including the full exercise by the underwriters of their option to purchase up to an additional 11,250,000 shares of Medline’s Class A common stock. Medline did not sell any shares of Class A common stock in the offering and did not receive any of the proceeds from the sale. Goldman Sachs & Co. LLC, Morgan Stanley, BofA Securities and J.P. Morgan acted as global...

Continue reading

TLGY Acquisition Corp. and StablecoinX Assets Inc. Announce Shareholder Approval of Business Combination

NEW YORK, NY, March 10, 2026 (GLOBE NEWSWIRE) — TLGY Acquisition Corp. (“TLGY”) (OTC: TLGYF) and StablecoinX Assets Inc. (“SC Assets”) announced today that that their previously announced business combination (the “Business Combination”) was approved by TLGY’s shareholders during the extraordinary general meeting of its shareholders held today in which approximately 97% of the votes cast were voted in favor of the Business Combination and related proposals presented to shareholders. The parties plan to complete the Business Combination as soon as possible, subject to satisfaction of all other remaining closing conditions. Upon the closing of the Business Combination, the combined company will be named StablecoinX Inc. (“StablecoinX”) and its Class A common stock is expected to be listed on Nasdaq under the ticker symbol “USDE”. About...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.